Richard King Mellon Foundation 4
4 · Trevi Therapeutics, Inc. · Filed May 13, 2019
Insider Transaction Report
Form 4
Richard King Mellon Foundation
10% Owner
Transactions
- Purchase
Common Stock
2019-05-09$10.00/sh+100,000$1,000,000→ 347,157 total - Conversion
Common Stock
2019-05-09+222,816→ 222,816 total - Other
Common Stock
2019-05-09+24,341→ 247,157 total - Conversion
Series C Preferred Stock
2019-05-09−1,908,450→ 0 total→ Common Stock (222,816 underlying)
Footnotes (2)
- [F1]On May 9, 2019, the Series C Preferred Stock, and the dividends that had accrued thereon to date, converted into Common Stock on a 9.5-for-one basis without payment of further consideration automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]Consists of shares transferred to Richard King Mellon Foundation by TPG Biotechnology Partners III, L.P. in connection with the closing of the Issuer's initial public offering.